Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Defining Variations in Survival of BRCA1and BRCA2Mutation Carriers

Defining Variations in Survival of BRCA1and BRCA2Mutation Carriers Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers tumor mutations, 20 also had germline BRCA2 mutations, Victor R. Grann, MD, MPH including 5 that were 6174delT and the remainder that Ramon E. Parsons, MD, PhD were somatically acquired. The investigators found significant differences in sur- N THE SECOND HALF OF THE 20TH CENTURY, WOMEN WITH vival and response to chemotherapy according to BRCA mu- a family history of breast cancer were treated with bi- tation status. Among the women in these cohorts, 225 had lateral mastectomies. Among 639 such women in 1 study, ovarian cancers that were sensitive to treatment, and 36 had Ithe median length of survival after surgery was 14 years. tumors that were treatment resistant (and 55 were missing Using their sisters as control participants, there was a large primary treatment outcomes). Of 192 patients eligible for survival difference between women who underwent bilat- drug (platinum)-free survival analysis, data were available eral mastectomies and those who did not. By the 1990s, af- for 163 patients (and missing from 29). Survival among pa- ter the identification of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Defining Variations in Survival of BRCA1and BRCA2Mutation Carriers

Grann, Victor R.; Parsons, Ramon E.
JAMA , Volume 306 (14) – Oct 12, 2011
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/defining-variations-in-survival-of-brca1and-brca2mutation-carriers-2KAhvNfoYq

References (15)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2011.1476
pmid
21990304
Publisher site
See Article on Publisher Site

Abstract

Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers tumor mutations, 20 also had germline BRCA2 mutations, Victor R. Grann, MD, MPH including 5 that were 6174delT and the remainder that Ramon E. Parsons, MD, PhD were somatically acquired. The investigators found significant differences in sur- N THE SECOND HALF OF THE 20TH CENTURY, WOMEN WITH vival and response to chemotherapy according to BRCA mu- a family history of breast cancer were treated with bi- tation status. Among the women in these cohorts, 225 had lateral mastectomies. Among 639 such women in 1 study, ovarian cancers that were sensitive to treatment, and 36 had Ithe median length of survival after surgery was 14 years. tumors that were treatment resistant (and 55 were missing Using their sisters as control participants, there was a large primary treatment outcomes). Of 192 patients eligible for survival difference between women who underwent bilat- drug (platinum)-free survival analysis, data were available eral mastectomies and those who did not. By the 1990s, af- for 163 patients (and missing from 29). Survival among pa- ter the identification of

Journal

JAMA – American Medical Association

Published: Oct 12, 2011

There are no references for this article.